References
- Bell GB. Spinal cord injury, pressure ulcers, and support surfaces. Ostomy Wound Manage 1999; 45: 48–53
- Caliri MH. Spinal cord injury and pressure ulcers. Nurs Clin North Am 2005; 40: 337–47
- Gefen A, Gefen N, Linder-Ganz E, Margulies SS. In vivo muscle stiffening under bone compression promotes deep pressure sores. J Biomech Eng 2005; 127: 512–24
- Liu P, Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am 2003; 17: 599–613
- Müller M, de la Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004; 48: 1441–53
- Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004; 64: 1621–42
- Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 2004; 64: 2347–77
- Dalhoff A, Petersen U, Endermann E. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410–25
- Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of Bay 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101–6
- Parish LC, Routh HB, Miskin B, Fidelholtz J, Werschler P, Heyd A, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000; 54: 497–503
- Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005; 26: 357–65
- Müller M, Stass H, Brunner M, Möller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345–9
- Joukhadar C, Stass H, Müller-Zellenberg U, Lackner E, Kovar F, Minar E, Müller M. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 2003; 47: 3099–103
- Brunner M, Pernerstorfer T, Mayer BX, Eichler HG, Müller M. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 2000; 28: 1754–9
- Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385–91
- Clough GF, Boutsiouki P, Church MK, Michel CC. Effects of blood flow on the in vivo recovery of a small diffusible molecule by microdialysis in human skin. J Pharmacol Exp Ther 2002; 302: 681–6
- Joukhadar C, Klein N, Frossard M, Minar E, Stass H, Lackner E, et al. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Clin Pharmacol Ther 2001; 70: 532–9
- Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163–74
- Joukhadar C, Klein N, Frossard M, Minar E, Stass H, Lackner E, et al. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Clin Pharmacol Ther 2001; 70: 532–9
- Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates. Part I: in vitro and animal models. Ann Pharmacother 2003; 37: 1287–98
- Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 2003; 37: 1478–88
- Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, Nord CE, Lode H. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis 2002; 34: 898–903
- Burkhardt O, Stass H, Thuss U, Borner K, Welte T. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Clin Pharmacokinet 2005; 44: 969–76
- Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new fluoroquinolones. Eur J Clin Microbiol Infect Dis 2003; 22: 203–21